Use of in vitro Dynamic Colon Model (DCM) to inform a physiologically based biopharmaceutic model (PBBM) to predict the in vivo performance of a modified-release formulation of theophylline

Stamatopoulos, Konstantinos and O’Farrell, Connor and Simmons, Mark J. H. and Batchelor, Hannah K. and Mistry, Nena (2023) Use of in vitro Dynamic Colon Model (DCM) to inform a physiologically based biopharmaceutic model (PBBM) to predict the in vivo performance of a modified-release formulation of theophylline. Pharmaceutics, 15 (3). 882. ISSN 1999-4923 (https://doi.org/10.3390/pharmaceutics15030882)

[thumbnail of Stamatopoulos-etal-Pharmaceutics-2023-Use-of-in-vitro-Dynamic-Ccolon-Model]
Preview
 Text. Filename: Stamatopoulos_etal_Pharmaceutics_2023_Use_of_in_vitro_Dynamic_Ccolon_Model.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (7MB)| Preview

Abstract

A physiologically based biopharmaceutic model (PBBM) of a modified-release formulation of theophylline (Uniphyllin Continus® 200 mg tablet) was developed and implemented to predict the pharmacokinetic (PK) data of healthy male volunteers by integrating dissolution profiles measured in a biorelevant in vitro model: the Dynamic Colon Model (DCM). The superiority of the DCM over the United States Pharmacopeia (USP) Apparatus II (USP II) was demonstrated by the superior predictions for the 200 mg tablet (average absolute fold error (AAFE): 1.1–1.3 (DCM) vs. 1.3–1.5 (USP II). The best predictions were obtained using the three motility patterns (antegrade and retrograde propagating waves, baseline) in the DCM, which produced similar PK profiles. However, extensive erosion of the tablet occurred at all agitation speeds used in USP II (25, 50 and 100 rpm), resulting in an increased drug release rate in vitro and overpredicted PK data. The PK data of the Uniphyllin Continus® 400 mg tablet could not be predicted with the same accuracy using dissolution profiles from the DCM, which might be explained by differences in upper gastrointestinal (GI) tract residence times between the 200 and 400 mg tablets. Thus, it is recommended that the DCM be used for dosage forms in which the main release phenomena take place in the distal GI tract. However, the DCM again showed a better performance based on the overall AAFE compared to the USP II. Regional dissolution profiles within the DCM cannot currently be integrated into Simcyp®, which might limit the predictivity of the DCM. Thus, further compartmentalization of the colon within PBBM platforms is required to account for observed intra-regional differences in drug distribution.

CORE (COnnecting REpositories)